Trinity Capital Inc. announced the commitment of $45 million in growth capital to Rapid Micro Biosystems, an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products.

Rapid Micro specializes in automating microbial quality control in mission-critical applications such as environmental monitoring, water testing, sterility testing and bioburden testing. The Company's Growth Direct platform provides faster results, greater accuracy, increased operational efficiency and stronger data integrity, enabling customers to make quicker decisions that help ensure a safe and consistent supply of important healthcare products.

"In an industry where quality cannot be compromised, Rapid Micro Biosystems is delivering the automation and dependability manufacturers need," said Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital. "They are transforming a critical process within biopharma manufacturing, and we are proud to partner with a team driving meaningful impact across the industry."

This new capital will help scale Rapid Micro's operations, to include supporting the continued global commercial expansion of the Growth Direct platform, and ongoing investments to drive gross margin expansion through product cost reduction, increased manufacturing efficiencies, and service productivity.

"We are pleased to partner with Trinity Capital, who shares our vision of automating manual microbial quality control testing methods used in biopharma manufacturing," said Robert Spignesi, President and CEO of Rapid Micro Biosystems. "This facility significantly strengthens our financial position and supports our continued focus on long-term revenue growth, margin expansion, and increasing shareholder value."